Project Grant R01CA307209
Award Date 8/24/26
Completion Date 7/31/31
Dollars Obligated $614K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Miami, FL 33136, USA
Similar Awards
- The National Cancer Institute awarded the University of Miami $547,621 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate (R)-ND336, a selective MMP14 inhibitor, as a means to overcome therapeutic resistance in glioblastoma and enhance response to chemoradiation and immunotherapy. The research addresses glioblastoma's "cold" tumor microenvironment and poor immunotherapy response by targeting MMP14, which stabilizes replication forks and...
- The National Cancer Institute awarded University of Massachusetts Medical School $1.06 million on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to engineer multi-targeted nanoparticle-based immunotherapy for pancreatic cancer. The funded work develops lipid-based nanoparticles (NPs) carrying RAS pathway inhibitors (trametinib, palbociclib, or RMC-7977) and STING/TLR4 innate immune agonists, designed to home specifically to tumor cells and dendritic cells within the...
- The National Cancer Institute awarded the University of Miami $529,260 on June 22, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate lactic acid sensing as a therapeutic vulnerability in clear cell renal cell carcinoma. The research examines the role of extracellular lactate in the tumor microenvironment as a self-signal driving tumor aggressiveness. The recipient has identified the G-protein coupled receptor GPR132 as a tumor dependency mechanism and proposes it...
- The National Cancer Institute awarded the University of Miami $606,219 on July 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to support signal transduction, cell biology, and molecular pharmacology research on the olfactory G protein-coupled receptor OR51E1. The recipient is developing high-throughput screening and computational platforms to identify novel small-molecule agonists and antagonists for OR51E1, an olfactory receptor expressed ectopically in prostate cancer and...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded the Regents of the University of Michigan $669,278 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop microbial-based cancer therapeutics engineered to deliver localized immune activation while minimizing systemic toxicity. The research focuses on nonpathogenic, tumor-tropic E. coli engineered to display membrane-anchored cytokines, specifically decoy-resistant...
- The National Cancer Institute awarded The University of Chicago $518,151 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate nicotinamide N-methyltransferase (NNMT) inhibition as a strategy to sensitize ovarian and colorectal cancers to immune checkpoint inhibitors. The award funds research targeting NNMT expression in cancer-associated fibroblasts within the tumor microenvironment. The project will investigate whether NNMTI'960, a small-molecule NNMT...
- The National Cancer Institute awarded the University of Virginia $529,456 on August 5, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate how inhibition of the ufmylation protein pathway enhances anti-tumor immunity and converts immunologically cold tumors into responsive ones. The project uses genetic and chemical inhibitors of the UBA5 protein—a key component of the ufmylation posttranslational modification pathway—to test whether ufmylation inhibition reduces...
- The National Cancer Institute awarded the University of Miami $110,228 on December 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research defining how pancreatic ductal adenocarcinoma remodels the tumor microenvironment to facilitate metastatic outgrowth. The project investigates fundamental differences between primary and metastatic pancreatic cancer stromal microenvironments and the fibroinflammatory signaling networks governing them. Aim 1 characterizes key...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $697,131 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate myeloid-stromal interactions that drive immune suppression in colorectal cancer and to evaluate therapeutic strategies targeting these pathways. The research addresses the immunological resistance of microsatellite-stable colorectal cancer to immune checkpoint blockade, particularly in patients with liver metastases. The...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded the University of Rochester $624,494 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate combined stereotactic body radiotherapy and interleukin-12 messenger RNA nanotechnology as a treatment strategy for pancreatic ductal adenocarcinoma. The research targets T cell dynamics in the pancreatic cancer tumor microenvironment by combining localized stereotactic body...